Efstratios Karagiannidis1, Georgios Sofidis1, Andreas S Papazoglou1, Olga Deda2,3, Eleftherios Panteris2,3, Dimitrios V Moysidis1, Nikolaos Stalikas1, Anastasios Kartas1, Anastasios Papadopoulos4, Leandros Stefanopoulos5, Haralambos Karvounis1, Helen Gika2,3, Georgios Theodoridis3,6, Georgios Sianos7. 1. First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece. 2. Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. 3. Biomic_AUTh, CIRI-AUTH Center for Interdisciplinary Research and Innovation Aristotle University of Thessaloniki, 57001, Thessaloniki, Greece. 4. 1St Propaedeutic Internal Medicine Department, AHEPA Hospital Aristotle University of Thessaloniki, Thessaloniki, Greece. 5. Lab of Computing, Medical Informatics and Biomedical Imaging Technologies, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. 6. Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece. 7. First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece. gsianos@auth.gr.
Abstract
BACKGROUND: Coronary artery disease (CAD) remains one of the leading causes of mortality and morbidity worldwide. As oxygen and nutrient supply to the myocardium significantly decrease during ischemic periods, important changes occur regarding myocardial intermediary energy metabolism. Metabolomics is an emerging field in systems biology, which quantifies metabolic changes in response to disease progression. This study aims to evaluate the diagnostic utility of plasma metabolomics-based biomarkers for determining the complexity and severity of CAD, as it is assessed via the SYNTAX score. METHODS: Corlipid is a prospective, non-interventional cohort trial empowered to enroll 1065 patients with no previous coronary intervention history, who undergo coronary angiography in University Hospital AHEPA, Thessaloniki. Venous blood samples are collected before coronary angiography. State-of the-art analytical methods are performed to calculate the serum levels of novel biomarkers: ceramides, acyl-carnitines, fatty acids, and proteins such as galectin-3, adiponectin, and the ratio of apolipoprotein B/apolipoprotein A1. Furthermore, all patients will be categorized based on the indication for coronary angiography (acute coronary syndrome, chronic coronary syndrome, preoperative coronary angiography) and on the severity of CAD using the SYNTAX score. Follow-up of 12 months after enrollment will be performed to record the occurrence of major adverse cardiovascular events. A risk prediction algorithm will be developed by combining clinical characteristics with established and novel biomarkers to identify patients at high risk for complex CAD based on their metabolite signatures. The first patient was enrolled in July 2019 and completion of enrollment is expected until May 2021. DISCUSSION: CorLipid is an ongoing trial aiming to investigate the correlation between metabolic profile and complexity of coronary artery disease in a cohort of patients undergoing coronary angiography with the potential to suggest a decision-making tool with high discriminative power for patients with CAD. To our knowledge, Corlipid is the first study aspiring to create an integrative metabolomic biomarkers-based algorithm by combining metabolites from multiple classes, involved in a wide range of pathways with well-established biochemical markers. Trial registration CorLipid trial registration: ClinicalTrials.gov number: NCT04580173. Registered 8 October 2020-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04580173 .
BACKGROUND:Coronary artery disease (CAD) remains one of the leading causes of mortality and morbidity worldwide. As oxygen and nutrient supply to the myocardium significantly decrease during ischemic periods, important changes occur regarding myocardial intermediary energy metabolism. Metabolomics is an emerging field in systems biology, which quantifies metabolic changes in response to disease progression. This study aims to evaluate the diagnostic utility of plasma metabolomics-based biomarkers for determining the complexity and severity of CAD, as it is assessed via the SYNTAX score. METHODS:Corlipid is a prospective, non-interventional cohort trial empowered to enroll 1065 patients with no previous coronary intervention history, who undergo coronary angiography in University Hospital AHEPA, Thessaloniki. Venous blood samples are collected before coronary angiography. State-of the-art analytical methods are performed to calculate the serum levels of novel biomarkers: ceramides, acyl-carnitines, fatty acids, and proteins such as galectin-3, adiponectin, and the ratio of apolipoprotein B/apolipoprotein A1. Furthermore, all patients will be categorized based on the indication for coronary angiography (acute coronary syndrome, chronic coronary syndrome, preoperative coronary angiography) and on the severity of CAD using the SYNTAX score. Follow-up of 12 months after enrollment will be performed to record the occurrence of major adverse cardiovascular events. A risk prediction algorithm will be developed by combining clinical characteristics with established and novel biomarkers to identify patients at high risk for complex CAD based on their metabolite signatures. The first patient was enrolled in July 2019 and completion of enrollment is expected until May 2021. DISCUSSION: CorLipid is an ongoing trial aiming to investigate the correlation between metabolic profile and complexity of coronary artery disease in a cohort of patients undergoing coronary angiography with the potential to suggest a decision-making tool with high discriminative power for patients with CAD. To our knowledge, Corlipid is the first study aspiring to create an integrative metabolomic biomarkers-based algorithm by combining metabolites from multiple classes, involved in a wide range of pathways with well-established biochemical markers. Trial registration CorLipid trial registration: ClinicalTrials.gov number: NCT04580173. Registered 8 October 2020-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04580173 .
Authors: Susan Cheng; Svati H Shah; Elizabeth J Corwin; Oliver Fiehn; Robert L Fitzgerald; Robert E Gerszten; Thomas Illig; Eugene P Rhee; Pothur R Srinivas; Thomas J Wang; Mohit Jain Journal: Circ Cardiovasc Genet Date: 2017-04
Authors: Robert W McGarrah; Scott B Crown; Guo-Fang Zhang; Svati H Shah; Christopher B Newgard Journal: Circ Res Date: 2018-04-27 Impact factor: 17.367
Authors: Aurelian Bidulescu; Lloyd E Chambless; Anna Maria Siega-Riz; Steven H Zeisel; Gerardo Heiss Journal: BMC Cardiovasc Disord Date: 2007-07-13 Impact factor: 2.298
Authors: Efstratios Karagiannidis; Dimitrios V Moysidis; Andreas S Papazoglou; Eleftherios Panteris; Olga Deda; Nikolaos Stalikas; Georgios Sofidis; Anastasios Kartas; Alexandra Bekiaridou; George Giannakoulas; Helen Gika; George Theodoridis; Georgios Sianos Journal: Cardiovasc Diabetol Date: 2022-05-07 Impact factor: 9.951
Authors: Andreas S Papazoglou; Ioannis T Farmakis; Stefanos Zafeiropoulos; Dimitrios V Moysidis; Efstratios Karagiannidis; Nikolaos Stalikas; Anastasios Kartas; Konstantinos Stamos; Georgios Sofidis; Ioannis Doundoulakis; Georgios Giannopoulos; George Giannakoulas; Georgios Sianos Journal: Front Cardiovasc Med Date: 2022-07-22
Authors: Olga Deda; Eleftherios Panteris; Thomas Meikopoulos; Olga Begou; Thomai Mouskeftara; Efstratios Karagiannidis; Andreas S Papazoglou; Georgios Sianos; Georgios Theodoridis; Helen Gika Journal: Biomolecules Date: 2022-02-23